Yoichi Naito
About
Yoichi Naito is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Yoichi Naito has authored 150 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Oncology, 72 papers in Pulmonary and Respiratory Medicine and 35 papers in Cancer Research. Recurrent topics in Yoichi Naito's work include HER2/EGFR in Cancer Research (34 papers), Cancer Treatment and Pharmacology (29 papers) and Advanced Breast Cancer Therapies (20 papers). Yoichi Naito is often cited by papers focused on HER2/EGFR in Cancer Research (34 papers), Cancer Treatment and Pharmacology (29 papers) and Advanced Breast Cancer Therapies (20 papers). Yoichi Naito collaborates with scholars based in Japan, United States and United Kingdom. Yoichi Naito's co-authors include Toshihiko Doi, Nobuaki Matsubara, Toshirou Nishida, Kohei Shitara, Yutaka Nishiwaki, Hirofumi Mukai, Tetsuya Urasaki, Kaoru Kubota, Yasutoshi Kuboki and Nagahiro Saijo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.
In The Last Decade
Yoichi Naito
141 papers receiving 2.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Yoichi Naito Japan | 27 | 1.7k | 1.1k | 623 | 428 | 355 | 150 | 2.7k | ||
| Yasutoshi Kuboki Japan | 27 | 2.1k 1.2× | 1.2k 1.1× | 556 0.9× | 309 0.7× | 298 0.8× | 143 | 2.8k | ||
| Jifang Gong China | 29 | 1.7k 1.0× | 928 0.9× | 785 1.3× | 603 1.4× | 381 1.1× | 147 | 2.9k | ||
| Tania Fleitas Spain | 19 | 1.1k 0.7× | 1.1k 1.0× | 577 0.9× | 570 1.3× | 309 0.9× | 58 | 2.3k | ||
| Chia‐Chi Lin Taiwan | 25 | 2.1k 1.2× | 1.3k 1.2× | 799 1.3× | 391 0.9× | 627 1.8× | 62 | 3.5k | ||
| Andreas H. Marx Germany | 26 | 1.3k 0.8× | 822 0.8× | 698 1.1× | 301 0.7× | 177 0.5× | 75 | 2.2k | ||
| Akin Atmaca Germany | 24 | 2.2k 1.3× | 1.4k 1.3× | 845 1.4× | 304 0.7× | 505 1.4× | 61 | 3.3k | ||
| María Alsina Spain | 22 | 1.3k 0.8× | 1.3k 1.2× | 595 1.0× | 286 0.7× | 177 0.5× | 109 | 2.5k | ||
| Hee Eun Lee South Korea | 29 | 1.3k 0.8× | 707 0.7× | 1.0k 1.6× | 680 1.6× | 142 0.4× | 86 | 2.7k | ||
| Virginia Ferraresi Italy | 25 | 1.3k 0.8× | 1.0k 1.0× | 635 1.0× | 247 0.6× | 370 1.0× | 125 | 2.4k | ||
| Thomas A. Puchalski United States | 24 | 1.5k 0.9× | 834 0.8× | 905 1.5× | 413 1.0× | 789 2.2× | 51 | 2.8k |
Countries citing papers authored by Yoichi Naito
Since
Specialization
Citations
This map shows the geographic impact of Yoichi Naito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoichi Naito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoichi Naito more than expected).
Fields of papers citing papers by Yoichi Naito
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yoichi Naito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoichi Naito. The network helps show where Yoichi Naito may publish in the future.
Co-authorship network of co-authors of Yoichi Naito
This figure shows the co-authorship network connecting the top 25 collaborators of Yoichi Naito. A scholar is included among the top collaborators of Yoichi Naito based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoichi Naito. Yoichi Naito is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yap, Timothy A., Jonathan W. Goldman, Shaveta Vinayak, et al.. (2025). First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer. Clinical Cancer Research. 31(14). 2899–2909.
2.
Fujisawa, Yasuhiro, Yasuo Yoshioka, Koji Yoshino, et al.. (2025). Secondary Publication of Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Cutaneous Angiosarcoma 2025. The Journal of Dermatology. 52(10). e859–e875.
3.
Naito, Yoichi, Seigo Nakamura, Nobuko Kawaguchi‐Sakita, et al.. (2024). Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors. International Journal of Clinical Oncology. 29(11). 1684–1695.
4.
Harano, Kenichi, et al.. (2024). Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance. Gynecologic Oncology Reports. 55. 101482–101482.
5.
Mukohara, Toru, et al.. (2024). Efficacy of Trametinib in Neurofibromatosis Type 1–Associated Gastrointestinal Stromal Tumors: A Case Report. JCO Precision Oncology. 8(8). e2300649–e2300649.
6.
Kuboki, Yasutoshi, Takafumi Koyama, Nobuaki Matsubara, et al.. (2024). PD ‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study. Cancer Medicine. 13(8). e6980–e6980.
7.
Li, Bob T., Funda Meric‐Bernstam, Aditya Bardia, et al.. (2023). 654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study. Annals of Oncology. 34. S459–S460.
8.
Naito, Yoichi, Yoshito Komatsu, Yukinori Kurokawa, et al.. (2023). 1917MO CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor. Annals of Oncology. 34. S1031–S1032.
9.
Hirota, Akira, Nobuyuki Takahashi, Hiromichi Nakajima, et al.. (2023). The impact of the COVID ‐19 pandemic on perioperative chemotherapy for breast cancer. Cancer Medicine. 12(11). 12095–12105.
10.
Taira, Naruto, Kosuke Kashiwabara, Junji Tsurutani, et al.. (2022). Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.. PubMed. 76(6). 661–671.
11.
Doi, Toshihiko, Kohei Shitara, Takashi Kojima, et al.. (2022). Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors. Cancer Science. 114(2). 574–585.
12.
Kawazoe, Akihito, Kota Itahashi, Noboru Yamamoto, et al.. (2021). TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704). Clinical Cancer Research. 27(24). 6709–6715.
13.
Doi, Toshihiko, Noboru Yamamoto, Yoichi Naito, et al.. (2021). Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study. Cancer Medicine. 10(19). 6579–6589.
14.
Tokunaga, Masanori, Reo Sato, Akihiko Yoshida, et al.. (2021). Gastric mesenchymal tumor with smooth muscle differentiation and echinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma kinase (EML4‐ALK) fusion. Pathology International. 71(10). 707–711.
15.
Naito, Yoichi, Yasutoshi Kuboki, Masafumi Ikeda, et al.. (2021). Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study. Investigational New Drugs. 39(6). 1568–1576.
16.
Doi, Toshihiko, Yasutoshi Kuboki, Yoichi Naito, et al.. (2021). A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors. Cancer Science. 113(3). 1010–1017.
17.
Sunami, Kuniko, Hideaki Bando, Yasushi Yatabe, et al.. (2021). Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA. Cancer Science. 112(9). 3911–3917.
18.
Minami, Hironobu, Toshihiko Doi, Masanori Toyoda, et al.. (2020). Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies. Cancer Science. 112(2). 725–733.
19.
Matsubara, Nobuaki, Yoichi Naito, Norio Yamamoto, et al.. (2017). Phase I expansion cohort of TAS-115, a novel oral MET/VEGFR/FMS inhibitor, for castration-resistant prostate cancer patients (CRPC pts) with bone metastases. Annals of Oncology. 28. v274–v274.
20.
Naito, Yoichi, Satoshi Tsuchiya, Shinichi Ishihara, et al.. (2008). Impact of Preexisting Pulmonary Fibrosis Detected on Chest Radiograph and CT on the Development of Gefitinib-Related Interstitial Lung Disease. American Journal of Clinical Oncology. 31(4). 340–344.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Yasutoshi Kuboki Breakdown of academic impact, for papers by Jifang Gong Breakdown of academic impact, for papers by Tania Fleitas Breakdown of academic impact, for papers by Chia‐Chi Lin Breakdown of academic impact, for papers by Andreas H. Marx Breakdown of academic impact, for papers by Akin Atmaca Breakdown of academic impact, for papers by María Alsina Breakdown of academic impact, for papers by Hee Eun Lee Breakdown of academic impact, for papers by Virginia Ferraresi Breakdown of academic impact, for papers by Thomas A. Puchalski